The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 05, 2016
Filed:
Dec. 16, 2009
Applicants:
H. Andrew Strong, North Vancouver, CA;
Yong Hao, Vancouver, CA;
Inventors:
H. Andrew Strong, North Vancouver, CA;
Yong Hao, Vancouver, CA;
Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/409 (2006.01); A61K 31/555 (2006.01); A61K 31/573 (2006.01); A61K 39/395 (2006.01); C07K 16/22 (2006.01); A61K 41/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/409 (2013.01); A61K 31/573 (2013.01); A61K 39/395 (2013.01); A61K 41/0071 (2013.01); C07K 16/22 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01);
Abstract
The use of a combination of photodynamic therapy and an anti-VEGF agent in the treatment of conditions characterized by unwanted choroidal neovasculature is described. These conditions include wet age-related macular degeneration Preferred anti-VEGF agents are antibodies such as bevacizumab or ranibizumab Photosensitizers may be selected from green porphyrins such as BPD-MA (verteporfin) and the photodynamic activation of the photo sensitizer may be accomplished using a reduced fluence rate. The use may further comprises an anti-inflammatory agent such as dexamethasone.